Value | |
No. of patients | 61 |
Age, median (IQR) | 64 (19) |
BMI, median (IQR) | 29 (8) |
Ethnicity (%) | |
Caucasian | 57 (94) |
Any other mixed background | 2 (3) |
Unknown | 2 (3) |
BMI (%) | |
<25 | 9 (15) |
25–30 | 20 (33) |
>30 | 26 (42) |
Unknown | 6 (10) |
Comorbidities two or more (%) | |
Yes | 19 (31) |
No | 38 (62) |
Unknown | 4 (7) |
Histology (%) | |
Benign | 37 (60) |
Endometrioid | 19 (31) |
Serous | 3 (5) |
Endometrioid with small area clear cell | 1 (2) |
Mixed endometrioid/serous | 1 (2) |
FIGO stage (%)* | |
I | 16 (67) |
II | 1 (4) |
III | 3 (13) |
IV | 1 (4) |
Unknown | 3 (13) |
Grade (%)* | |
1 | 13 (54) |
2 | 7 (29) |
3 | 4 (17) |
Treatment (%)* | |
Surgery | 20 (83) |
Hormonal | 4 (17) |
Adjuvant therapy (%)† | |
Yes | 6 (25) |
No | 17 (68) |
Unknown | 1 (4) |
*Applicable for cancer group (n=24).
†Adjuvant therapy was either radiotherapy (vaginal vault brachytherapy and/or external beam radiation therapy), chemotherapy (carboplatin and paclitaxel), or a combination of the two.
BMI, body mass index (in kg/m2); FIGO, International Federation of Gynecology and Obstetrics.